Just saw Viatris got FDA acceptance for their supplemental drug application on phentolamine solution for presbyopia treatment. The regulator's looking at an October 2026 decision date. What's interesting is this drug is already out there treating pharmacologically-induced mydriasis under the Ryzumvi name, so they're basically expanding its use case. The Phase 3 trials (VEGA-2 and VEGA-3) hit their marks with no serious adverse events, which is solid. Stock popped over 1% on the news when I checked earlier. Pretty standard biotech approval process stuff, but worth watching if you're in the pharma space. Presbyopia is just age-related vision decline, so if this gets approved it could be a decent market opportunity. Not financial advice obviously, just tracking what's moving in healthcare.